Cardioplegic strategies to protect the hypertrophic heart during cardiac surgery

Perfusion

Volumn 26, Issue , 2011, Pages 48-56

  Suleiman, M S ^a   Hancock, M ^a   Shukla, R ^a   Rajakaruna, C ^a   Angelini, G D ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

aortic valve surgery; calcium; cardioplegia; cardiopulmonary bypass; hypertrophy; hypothermia; inflammation; ischaemia; oxidative stress

Indexed keywords

CALCIUM; REACTIVE OXYGEN METABOLITE;

AORTA VALVE; CARDIOMEGALY; CARDIOPULMONARY BYPASS; FEMALE; HEART ARREST; HEART MUSCLE CELL; HOMEOSTASIS; HUMAN; INFLAMMATION; MALE; METABOLISM; OXIDATIVE STRESS; REPERFUSION INJURY; REVIEW; VALVULAR HEART DISEASE;

AORTIC VALVE; CALCIUM; CARDIOMEGALY; CARDIOPULMONARY BYPASS; FEMALE; HEART ARREST, INDUCED; HEART VALVE DISEASES; HOMEOSTASIS; HUMANS; INFLAMMATION; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84855753129     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659111420607     Document Type: Article

References (80)

1. Suleiman M.S. Zacharowski K. Angelini G.D. Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics. Br J Pharmaco Jan 2008; 153(1): 21–33.
2. Suleiman M.S. Halestrap A.P. Griffiths E.J. Mitochondria: a target for myocardial protection. Pharmacol Ther Jan 2001; 89(1): 29–46.
3. Saini-Chohan H.K. Dhalla N.S. Attenuation of ischaemia-reperfusion-induced alterations in intracellular Ca2+ in cardiomyocytes from hearts treated with N-acetylcysteine and N-mercaptopropionylglycine. Can J Physiol Pharmacol Dec 2009; 87(12): 1110–1119.
4. Halestrap A.P. Clarke S.J. Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Act Aug 2007; 1767(8): 1007–1031.
5. Melrose D.G. Dreyer B. Bentall H.H. Baker J.B. Elective cardiac arrest. Lancet Jul 2 1955; 269(6879): 21–22.
6. Halestrap A.P. Mitochondria and reperfusion injury of the heart–a holey death but not beyond salvation. J Bioenerg Biomembr Apr 2009; 41(2): 113–121.
7. Saini H.K. Dhalla N.S. Defective calcium handling in cardiomyocytes isolated from hearts subjected to ischaemia-reperfusion. Am J Physiol Heart Circ Physiol May 2005; 288(5): H2260–H2270.
8. Chen Q. Camara A.K. Stowe D.F. Hoppel C.L. Lesnefsky E.J. Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischaemia and reperfusion. Am J Physiol Cell Physiol Jan 2007; 292(1): C137–C147.
9. Smith R.A. Murphy M.P. Animal and human studies with the mitochondria-targeted antioxidant Mito Q. Ann N Y Acad Sci Jul 2010; 1201:96–103.
10. Freyholdt T. Massoudy P. Zahler S. et al. Beneficial effect of sodium nitroprusside after coronary artery bypass surgery: pump function correlates inversely with cardiac release of proinflammatory cytokines. J Cardiovasc Pharmacoly Sep 2003; 42(3): 372–378.
11. Raja S.G. Dreyfus G.D. Modulation of systemic inflammatory response after cardiac surgery. Asian Cardiovasc Thorac Ann Dec 2005; 13(4): 382–395.
12. Lehmann L.E. Schroeder S. Hartmann W. et al. A single nucleotide polymorphism of macrophage migration inhibitory factor is related to inflammatory response in coronary bypass surgery using cardiopulmonary bypass. Eur J Cardiothorac Surg Jul 2006; 30(1): 59–63.
13. Christen S. Finckh B. Lykkesfeldt J. et al. Oxidative stress precedes peak systemic inflammatory response in pediatric patients undergoing cardiopulmonary bypass operation. Free Radic Biol Med May 15 2005; 38(10): 1323–1332.
14. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res Feb 15 2004; 61(3): 481–497.
15. Ren G. Dewald O. Frangogiannis N.G. Inflammatory mechanisms in myocardial infarction. Curr Drug Targets Inflamm Allergy Sep 2003; 2(3): 242–256.
16. Wang M. Baker L. Tsai B.M. Meldrum K.K. Meldrum D.R. Sex differences in the myocardial inflammatory response to ischaemia-reperfusion injury. Am J Physiol Endocrinol Metab Feb 2005; 288(2): E321–E326.
17. Chandrasekar B. Mitchell D.H. Colston J.T. Freeman G.L. Regulation of CCAAT/Enhancer binding protein, interleukin-6, interleukin-6 receptor, and gp130 expression during myocardial ischaemia/reperfusion. Circulation Jan 26 1999; 99(3): 427–433.
18. Sawa Y. Ichikawa H. Kagisaki K. Ohata T. Matsuda H. Interleukin-6 derived from hypoxic myocytes promotes neutrophil-mediated reperfusion injury in myocardium. J Thorac Cardiovasc Surg Sep 1998; 116(3): 511–517.
19. Dreyer W.J. Phillips S.C. Lindsey M.L. et al. Interleukin 6 induction in the canine myocardium after cardiopulmonary bypass. J Thorac Cardiovasc Surg Aug 2000; 120(2): 256–263.
20. Zahler S. Massoudy P. Hartl H. Hahnel C. Meisner H. Becker B.F. Acute cardiac inflammatory responses to postischaemic reperfusion during cardiopulmonary bypass. Cardiovasc Res Mar 1999; 41(3): 722–730.
21. Deten A. Volz H.C. Holzl A. Briest W. Zimmer H.G. Effect of propranolol on cardiac cytokine expression after myocardial infarction in rats. Mol Cell Biochem Sep 2003; 251(1-2): 127–137.
22. Goudeau J.J. Clermont G. Guillery O. et al. In high-risk patients, combination of antiinflammatory procedures during cardiopulmonary bypass can reduce incidences of inflammation and oxidative stress.J Cardiovasc Pharmacol Jan 2007; 49(1): 39–45.
23. Simonardottir L. Torfason B. Stefansson E. Magnusson J. Changes in muscle compartment pressure after cardiopulmonary bypass. Perfusion 2006; 21(3): 157–163.
24. Devereux R.B. Casale P.N. Hammond I.W. et al. Echocardiographic detection of pressure-overload left ventricular hypertrophy: effect of criteria and patient population.J Clin Hypertens Mar 1987; 3(1): 66–78.
25. Swynghedauw B. Delcayre C. Cheav S.L. Callens-el Amrani F. Biological basis of diastolic dysfunction of the hypertensive heart. Eur Heart J Sep 1992; 13 Suppl D: 2–8.
26. Frohlich E.D. Apstein C. Chobanian A.V. et al. The heart in hypertension. N Engl J Med Oct 1 1992; 327(14): 998–1008.
27. Kozhevnikov D. Caref E.B. El-Sherif N. Mechanisms of enhanced arrhythmogenicity of regional ischaemia in the hypertrophied heart. Heart Rhythm Apr 2009; 6(4): 522–527.
28. Sambandam N. Lopaschuk G.D. Brownsey R.W. Allard M.F. Energy metabolism in the hypertrophied heart. Heart Fail Rev Apr 2002; 7(2): 161–173.
29. Wu X. Zhang T. Bossuyt J. et al. Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest Mar 2006; 116(3): 675–682.
30. Wilkins B.J. Molkentin J.D. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun Oct 1 2004; 322(4): 1178–1191.
31. Zhang C.L. McKinsey T.A. Chang S. Antos C.L. Hill J.A. Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell Aug 23 2002; 110(4): 479–488.
32. Sugden P.H. Clerk A. “Stress-responsive” mitogen- activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res Aug 24 1998; 83(4): 345–352.
33. Ross R.S. Borg T.K. Integrins and the myocardium. Circ Res Jun 8 2001; 88(11): 1112–1119.
34. Brancaccio M. Fratta L. Notte A. et al. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med Jan 2003; 9(1): 68–75.
35. Heineke J. Ruetten H. Willenbockel C. et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc Natl Acad Sci U S A. Feb 1 2005; 102(5): 1655–1660.
36. Zou Y. Akazawa H. Qin Y. et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol Jun 2004; 6(6): 499–506.
37. Peng X. Kraus M.S. Wei H. et al. Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice. J Clin Invest Jan 2006; 116(1): 217–227.
38. Taegtmeyer H. Sen S. Vela D. Return to the fetal gene program: a suggested metabolic link to gene expression in the heart. Ann N Y Acad Sci Feb 2010; 1188:191–198.
39. Horowitz J.D. Chirkov Y.Y. Kennedy J.A. Sverdlov A.L. Modulation of myocardial metabolism: an emerging therapeutic principle. Curr Opin Cardiol Jul 2010; 25(4): 329–334.
40. Simko F. Spontaneous regression of left ventricular hypertrophy in a rabbit model of aortic insufficiency: possible clinical implications. Med Hypotheses Dec 1995; 45(6): 556–558.
41. Conway M.A. Bottomley P.A. Ouwerkerk R. Radda G.K. Rajagopalan B. Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation May 5 1998; 97(17): 1716–1723.
42. Suleiman M.S. Caputo M. Ascione R. et al. Metabolic differences between hearts of patients with aortic valve disease and hearts of patients with ischaemic disease. J Mol Cell Cardiol Nov 1998; 30(11): 2519–2523.
43. Zhu Y.C. Zhu Y.Z. Spitznagel H. Gohlke P. Unger T. Substrate metabolism, hormone interaction, and angiotensin-converting enzyme inhibitors in left ventricular hypertrophy. Diabetes Jan 1996; 45 Suppl 1: S59–S65.
44. King N. Lin H. McGivan J.D. Suleiman M.S. Expression and activity of the glutamate transporter EAAT2 in cardiac hypertrophy: implications for ischaemia reperfusion injury. Pflugers Arch Sep 2006; 452(6): 674–682.
45. Zhang Y. Xu S. Increased vulnerability of hypertrophied myocardium to ischaemia and reperfusion injury. relation to cardiac renin-angiotensin system. Chin Med J (Engl) Jan 1995; 108(1): 28–32.
46. Chase A. Jackson C.L. Angelini G.L. Suleiman M.S. Coronary artery disease progression is associated with increased resistance of hearts and myocytes to cardiac insults. Crit Care Med Oct 2007; 35(10): 2344–2351.
47. Ji L.L. Fu R.G. Mitchell E.W. Griffiths M. Waldrop T.G. Swartz H.M. Cardiac hypertrophy alters myocardial response to ischaemia and reperfusion in vivo. Acta Physiol Scand Jul 1994; 151(3): 279–290.
48. Itoh T. Abe K. Tokumura M. Hirono S. Haruna M. Ibii N. Cardiac mechanical dysfunction induced by ischaemia-reperfusion in perfused heart isolated from stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens Aug 2004; 26(6): 485–498.
49. Stamm C. Friehs I. Cowan D.B. et al. Inhibition of tumor necrosis factor-alpha improves postischemic recovery of hypertrophied hearts. Circulation Sep 18 2001; 104(12 Suppl 1): I350–I355.
50. Kleinbongard P. Schulz R. Heusch G. TNFα in myocardial ischaemia/reperfusion, remodeling and heart failure. Heart Fail Rev Jan 2011; 16(1): 49–69.
51. Kevelaitis E. Qureshi A.A. Mouas C. et al. Na+/H+ exchange inhibition in hypertrophied myocardium subjected to cardioplegic arrest: an effective cardioprotective approach. Eur J Cardiothorac Surg Jan 2005; 27(1): 111–116.
52. King N. Lin H. McGivan J.D. Suleiman M.S. Aspartate transporter expression and activity in hypertrophic rat heart and ischaemia-reperfusion injury. J Physiol May 1 2004; 556(Pt 3): 849–858.
53. Smolenski R.T. Jayakumar J. Seymour A.M. Yacoub M.H. Energy metabolism and mechanical recovery after cardioplegia in moderately hypertrophied rats. Mol Cell Biochem Mar 1998; 180(1-2): 137–143.
54. Hochhauser E. Leshem D. Kaminski O. Cheporko Y. Vidne B.A. Shainberg A. The protective effect of prior ischaemia reperfusion adenosine A1 or A3 receptor activation in the normal and hypertrophied heart. Interact Cardiovasc Thorac Surg Jun 2007; 6(3): 363–368.
55. Peng L.Y. Ma H. He J.G. et al. Ischemic postconditioning attenuates ischemia/reperfusion injury in isolated hypertrophied rat heart. Zhonghua Xin Xue Guan Bing Za Zhi. Aug 2006; 34(8): 685–689.
56. Beyersdorf F. Elert O. Satter P. Determination of maximal ischemic tolerance of the human heart by ultrastructural recording of preischemic degree of myocardial hypertrophy and degeneration. Ann Thorac Surg Oct 1980; 30(4): 356–363.
57. Calafiore A.M. Teodori G. Bosco G. et al. Intermittent antegrade warm blood cardioplegia in aortic valve replacement. J Card Surg Sep-Oct 1996; 11(5): 348–354.
58. Jin X.Y. Gibson D.G. Pepper J.R. Early changes in regional and global left ventricular function after aortic valve replacement. Comparison of crystalloid, cold blood, and warm blood cardioplegias. Circulation Nov 1 1995; 92(9 Suppl): II155–II162.
59. Anderson W.A. Berrizbeitia L.D. Ilkowski D.A. et al. Normothermic retrograde cardioplegia is effective in patients with left ventricular hypertrophy. A prospective and randomized study. J Cardiovasc Surg (Torino). Feb 1995; 36(1): 17–24.
60. Ovrum E. Tangen G. Tollofsrud S. Oystese R. Ringdal M.A. Istad R. Cold blood versus cold crystalloid cardioplegia: a prospective randomised study of 345 aortic valve patients. Eur J Cardiothorac Surg Dec 2010; 38(6): 745–749.
61. Braathen B. Tonnessen T. Cold blood cardioplegia reduces the increase in cardiac enzyme levels compared with cold crystalloid cardioplegia in patients undergoing aortic valve replacement for isolated aortic stenosis. J Thorac Cardiovasc Surg Apr 2010; 139(4): 874–880.
62. Caputo M. Bryan A.J. Calafiore A.M. Suleiman M.S. Angelini G.D. Intermittent antegrade hyperkalaemic warm blood cardioplegia supplemented with magnesium prevents myocardial substrate derangement in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg Dec 1998; 14(6): 596–601.
63. Salhiyyah K. Raja S.G. Akeela H. Pepper J. Amrani M. Beating heart continuous coronary perfusion for valve surgery: what next for clinical trials? Future Cardiol Nov 2010; 6(6): 845–858.
64. Trunk P. Gersak B. Comparison of serum troponin I and plasma lactate concentrations in arrested versus beating-heart aortic valve replacement. J Heart Valve Dis Nov 2010; 19(6): 716–722.
65. Macedo F.I. Carvalho E.M. Hassan M. Ricci M. Gologorsky E. Salerno T.A. Beating heart valve surgery in patients with low left ventricular ejection fraction. J Card Surg May 2010; 25(3): 267–271.
66. Khuri S.F. Warner K.G. Josa M. et al. The superiority of continuous cold blood cardioplegia in the metabolic protection of the hypertrophied human heart. J Thorac Cardiovasc Surg Mar 1988; 95(3): 442–454.
67. Karadeniz U. Erdemli O. Yamak B. et al. On-pump beating heart versus hypothermic arrested heart valve replacement surgery. J Card Surg Mar-Apr 2008; 23(2): 107–113.
68. Luo W. Li B. Chen R. Huang R. Lin G. Effect of ischaemic postconditioning in adult valve replacement. Eur J Cardiothorac Surg Feb 2008; 33(2): 203–208.
69. Hausenloy D.J. Yellon D.M. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res Aug 1 2008; 79(3): 377–386.
70. Ali N. Rizwi F. Iqbal A. Rashid A. Induced remote ischaemic pre-conditioning on ischaemia-reperfusion injury in patients undergoing coronary artery bypass. J Coll Physicians Surg Pak Jul 2010; 20(7): 427–431.
71. Venugopal V. Hausenloy D.J. Ludman A. et al. Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial. Heart Oct 2009; 95(19): 1567–1571.
72. Thielmann M. Kottenberg E. Boengler K. et al. Remote ischaemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol Sep 2010; 105(5): 657–664.
73. Li L. Luo W. Huang L. et al. Remote perconditioning reduces myocardial injury in adult valve replacement: a randomized controlled trial. J Surg Res Nov 2010; 164(1): e21–e26.
74. Dussin L.H. Moura L. Gib M.C. Saadi E.K. Barbosa G.V. Wender O.C. Ultrastructural study of the myocardium using cardioplegic crystalloid solution with and without procaine in patients undergoing aortic valve replacement. Rev Bras Cir Cardiovasc Sep 2008; 23(3): 389–395.
75. Onorati F. Renzulli A. De Feo M. et al. Myocardial protection with insulin cardioplegia: who can really benefit? J Cardiovasc Surg (Torino) Dec 2005; 46(6): 569–576.
76. Takeuchi K. Akimoto H. Maida K. et al. Myocardial protection of the pressure overload hypertrophied heart in human cardiac surgery by acceleration of anaerobic glycolysis. J Cardiovasc Surg (Torino) Feb 2002; 43(1): 37–41.
77. Sawa Y. Taniguchi K. Kadoba K. et al. Leukocyte depletion attenuates reperfusion injury in patients with left ventricular hypertrophy. Circulation May 1 1996; 93(9): 1640–1646.
78. Sawa Y. Matsuda H. Myocardial protection with leukocyte depletion in cardiac surgery. Semin Thorac Cardiovasc Surg Jan 2001; 13(1): 73–81.
79. Yilmaz A. Rehman A. Sonker U. Kloppenburg G.T. Minimal access aortic valve replacement using a minimal extracorporeal circulatory system. Ann Thorac Surg Mar 2009; 87(3): 720–725.
80. Bahamondes S.J. Merino S.G. Salman A.J. Silva V.A. Droguett G.J. Ministernotomy for aortic valve surgery: report of 20 patients. Rev Med Chil Sep 2008; 136(9): 1141–1146.